Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Prof. Chrystal Paulos cancer immunologist ROCKSTAR at Emory University School of Medicine & a recipient of this year’s Fondazione Melanoma award gives major lecture on their new TH17 TIL ( PolarTIL ) that they are moving to the clinic! Preclinical data shows these PolarTIL are much more therapeutic and drive Ab responses against the tumor. They also show that Ab plays a role in the improved therapeutic efficacy.
Dr. Paulos & her colleague / “intellectual tennis partner” Gregory Lesinski – A truly DYNAMIC DUO.”
More posts featuring Bernard A. Fox.
